Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + nedaplatin
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + nedaplatin is a chemotherapeutic combination regimen consisting of gemcitabine, a nucleoside metabolic inhibitor, and nedaplatin, a platinum-based agent. Gemcitabine works as a prodrug that is transformed into active metabolites that replace building blocks of nucleic acids during DNA elongation, arresting tumor growth and promoting apoptosis of malignant cells. This combination has shown efficacy in treating various types of cancer, particularly non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
- Other names
- NG
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + nedaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + nedaplatin.